Evidence map›Paper›PMID 30697255›Full record

ArticleArchives of medical science : AMS2019

Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention.

Rafał N Wlazeł, Marta Migała, Marzenna Zielińska, Lucjan Pawlicki, Kinga Rośniak-Bąk, Iwona Szadkowska

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rafał N WlazełDepartment of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, Lodz, Poland.
Marta MigałaDepartment of Intensive Cardiac Therapy, Medical University of Lodz, Lodz, Poland.
Marzenna ZielińskaDepartment of Intensive Cardiac Therapy, Medical University of Lodz, Lodz, Poland.
Lucjan PawlickiDepartment of Internal Diseases and Cardiological Rehabilitation, Medical University of Lodz, Lodz, Poland.
Kinga Rośniak-BąkDepartment of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, Lodz, Poland.
Iwona SzadkowskaDepartment of Internal Diseases and Cardiological Rehabilitation, Medical University of Lodz, Lodz, Poland.
Medical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSoluble urokinase plasminogen activator receptor (suPAR) level reflects the general condition of the organism and was proved to give independent information in risk stratification of patients. The aim of this study was to assess the usefulness of suPAR in the prediction of adverse cardiac events in patients with first myocardial infarction (MI) undergoing primary percutaneous coronary intervention. Additionally, the diagnostic power of suPAR was assessed. MATERIAL AND

methodsOne hundred and thirty-nine of 150 consecutive patients were included in the study. Serum suPAR level (ELISA, Virogates) as well as C-reactive protein (on admission and at discharge) and maximum troponin T (assessed from successive 6-hour periods of blood collection) were measured. In the 1-year follow-up study the following major adverse cardiac events were observed: myocardial infarction, revascularization, stroke and death.

resultsMulti-variable analysis revealed prognostic usefulness only for suPAR and glomerular filtration rate:

conclusionsSoluble urokinase plasminogen activator receptor level appears to be an independent useful biomarker for the prediction of major adverse cardiac events early after first myocardial infarction. The biomarker's level seems to have more prognostic than diagnostic power.

Indexed as

biomarkerscardiovascular risk predictionprognostication after acute myocardial infarction

Identifiers

PMID30697255
PMCPMC6348361
OpenAlexW2588468560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.